clay.c/

Today, we're taking Manus out of the cloud and putting it on your desktop. Introducing My Computer, the core feature of the new Manus Desktop app. It’s your AI agent, now on your local machine.

Wife made me go to couples therapy last week Nice office Two couches Box of tissues The therapist asked what brings us in My wife said "he treats everything like a transaction" I said "that's not true" The therapist asked me to give an example of something I do that isn't transactional I thought about it for 11 seconds I could not think of an example The therapist asked how that made me feel I said "efficient" My wife looked at the therapist The therapist looked at my wife They had a moment I was not part of the moment My wife said "do you love me?" I said "I chose you. Every day I choose you. That's not emotion. That's a commitment with a compounding return and I don't see a better alternative in the market." The room went quiet My wife cried The therapist cried I didn't understand why That was the most romantic thing I've ever said The therapist said "I think we should meet weekly" I said "what's your hourly rate?" She said "$275" I said "for both of us or each?" My wife picked up her purse and walked out I stayed to negotiate the rate Got it down to $250 Small win Sent from my iPhone

Introducing Manus Agents — your personal Manus, now inside your chats. 👉🏻Long-term memory. Remembers your style, tone, and preferences. 👉🏻Full Manus power. Create videos, slides, websites, images from one message. 👉🏻Your tools, connected. Gmail, Calendar, Notion, and more. Available now on Telegram. More platforms coming soon.

BPC-157 and VEGF is a tricky subject because in some studies it promotes VEGF and in others in lowers VEGF, such as in a melanoma cell line model. Given we don’t know the true extent of BPC long term for VEGF, especially not in the injectbale form, and the data isn’t super useful, I’ve settled on the following in a frank risk/benefit discussion with patients with limited insight: 1. BPC-157 should not be used in active cancer or in people at high risk of cancers 2. A short course of BPC-157 for an acute injury, even if it was a uniform VEGF promoter would not be concerning for oncogenesis given it takes years even for the greatest carcinogens to take effect, but the patient should be educated about these risks As far as TB4 and TB500 go, we have a little bit more clarity but that isn’t saying much. In some cancers, TB4 levels are elevated. Given that these promote cell migration, would strongly oppose using them unchecked for long term, especially in active cancers or cancer prone individuals The most interesting ptoential use case of all of these compounds is short term, targeted uses, like BPC-157 for an acute MSK injury or TB4 in the post stroke setting More research is needed. (My team discussed this this am and we may have some good news soon :) )